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Immunization regimens that induce a broadly reactive cytolytic T lymphocyte (CTL) response specific for lentiviral antigens
have emerged as the leading candidates in efficacy trials conducted in both animal models and humans. To date, lentivirus
vaccination strategies have overlooked one such immunization strategy, namely the use of particulate antigens. To evaluate
the efficacy of targeting antigen into the phagocytic pathway to elicit a cell-mediated immune response to lentiviral antigens,
we initiated the first study of a particulate-based vaccination protocol using a large animal model system. Gradient-purified
equine infectious anemia virus (EIAV) was covalently coupled to glutaraldehyde-activated iron oxide beads. In vitro studies
demonstrated the effectiveness of the inactivated whole virus particulate to prime antigen presenting cells for the activation
and expansion of virus-specific CD81 CTL. The in vivo effectiveness of the particulate antigen was evaluated by experimental
immunization of ponies. Ponies receiving the viral particulate vaccine and challenged with infectious EIAV had a delayed
progression to disease and a reduced viral load compared with infected ponies that had not been vaccinated. Interestingly,
in vitro virus-specific CTL activity was detected in only one of four immunized animals at the day of challenge. The beneficial
effects of the particulate vaccine regimen were not clearly associated with any in vitro measurable parameters of the
virus-specific cellular or humoral immune responses elicited by the vaccine at the day of challenge. However, within 3 weeks
after virus challenge, anamnestic humoral responses characterized by a rapid emergence of neutralizing activity in the serum
and a predominance of conformationally dependent epitopes recognized by virus-specific antibodies were observed in the
vaccinates. Taken together, further studies are clearly warranted in large animal model systems using a particulate-based
vaccine regimen considering the beneficial effects of this regimen in our study and the protective effects of particulate
antigen delivery in the murine model. © 1999 Academic Press
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Equine infectious anemia virus (EIAV), a macrophage-
ropic lentivirus, causes in horses a persistent infection
nd a chronic disseminated disease of worldwide impor-
ance (Montelaro et al., 1993). The disease that develops
n the host after infection by EIAV via blood-feeding
nsects or blood from contaminated syringe needles (Is-
el and Foil, 1984; Stein et al., 1942) is characterized by
ecurring cycles of viremia and of clinical episodes char-
cterized by fever, anemia, edema, thrombocytopenia,
nd various wasting symptoms (Sellon et al., 1994).
mong lentiviruses, EIAV is unique in that despite ag-
ressive virus replication and rapid antigenic variation, a
arge majority of the infected animals progress from a
hronic disease state to an inapparent carrier stage that
an be immunologically maintained for life. It is interest-
ng for the development of candidate vaccine strategies
hat the animals survive the infection not by completely
learing the viral infection but rather by maintaining a
trict immunological control over virus replication. Thus
1 To whom reprint requests should be addressed at W1144 Biomed-
vcal Science Tower. E-mail: rmont@pop.pitt.edu.
37he lentivirus model system of EIAV offers a unique ad-
antage over other members of the lentiviral family in that
mmunological control of the viral infection by the host
oes occur and that the ability to induce a similar re-
ponse by novel immunization strategies therefore
hould be possible. Indeed, encouraging reports of var-
ous levels of vaccine protection in the EIAV model sys-
ems have been documented (Issel et al., 1992).
The development of an efficacious vaccine to control
nd/or prevent lentiviral infections remains a high priority
n human and veterinary medicine but also remains an
lusive goal. Many different antigenic preparations (pu-
ified viral protein, recombinant protein, peptides, im-
une stimulating complexes (ISCOMs), liposomes, and
o on) and recombinant vector strategies (vaccinia virus,
anary pox, adenovirus, retrovirus, and so on) have been
eveloped and implemented using multiple animal
odel systems to elicit protective immunity and to iden-
ify immune correlates of protection to lentiviral infec-
ions. The current wisdom in vaccine development is that
ne of the key, if not the key, parameter or parameters in
he host’s immunological arsenal necessary for the pre-
ention or control of lentiviral infection is a vigorous,
irus-specific cytolytic T lymphocyte (CTL) response. To
0042-6822/99 $30.00
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38 HAMMOND ET AL.rime the host with such virus-specific CTL to prevent or
ontrol an EIAV infection, we investigated the use of a
ecently described novel vaccination strategy, namely
argeting of antigen coupled to particulate beads into the
hagocytic pathway (Rock, 1996).
Antigens covalently associated to particulate beads
ave been successfully used to introduce various anti-
ens into the MHC class I restricted and, to a lesser
egree, the MHC class II restricted processing and pre-
entation pathways for the priming of a vigorous antigen-
pecific CTL response (Kovacsovics-Bankowski and
ock, 1994; Rock, 1996). Particulate antigen immuniza-
ion has been shown to prime CTLs that can protect
nimals from challenge with tumors (Falo et al., 1995).
xogenous antigens presented in particulate form are
redominantly taken up from the environment by phago-
ytes (Rock, 1996), which include macrophages, the pri-
ary target cell for EIAV replication in vivo (Montelaro et
l., 1993). Direction of antigen to the predominant target
f EIAV replication would seem most appropriate for the
nduction of a similar CTL response to that of an actively
nfected cell.
In this study, we covalently coupled gradient-purified
IAV virions to iron oxide beads. We evaluated the ca-
acity of this multicomponent particulate antigen prepa-
ation to be processed and presented by phagocytic
ells for recognition by virus-specific T cells in vitro and
o elicit immunity to EIAV in vivo. Immunized animals
ere experimentally infected with EIAV to determine the
n vivo effectiveness of the vaccine regimen. Immunolog-
cal responses induced by the vaccine regimen in the
nimals were measured using a panel of in vitro humoral
nd cellular analyses.
RESULTS
haracterization of the infectivity of EIAV covalently
oupled to particulates
We generated a preparation of gradient-purified EIAVPV
ovalently conjugated to glutaraldehyde-activated 0.5- to
.5-mm iron oxide beads (EIAV-beads) and evaluated its
otential use as a candidate vaccine to induce vigorous
ell-mediated immune responses. Immunization with
his particulate-based strategy required the delivery of
oninfectious virus to the animals. Therefore we as-
essed the infectivity of EIAV covalently attached to iron
xide beads by pulsing permissive cells, macrophages,
nd equine dermal cells with various preparations of
radient-purified EIAV and EIAV-beads. Levels of RT ac-
ivity in the culture supernatants were measured. Cul-
ures were considered productively infected if the aver-
ge measured RT activity in the supernatant of experi-
ental cultures were .2 S.D above the RT activity
easured in supernatants from uninfected cell cultures.
n equine dermal cell cultures (Fig. 1A) and equine mac-
ophage cultures (Fig. 1B), only the addition of gradient- wurified EIAV initiated a productive infection. Superna-
ants of both types of cell cultures on the addition of
IAV-beads treated with or without formaldehyde, a
nown inactivating agent of EIAV (Issel et al., 1992), or
radient-purified EIAV inactivated with formaldehyde
FIG. 1. Reverse transcriptase activity levels in the supernatants of
quine dermal cells (A) or equine macrophages (B) exposed to infectious
IAV and EIAV covalently coupled to iron oxide beads. Cells were incu-
ated with 3 mg/ml of gradient-purified EIAV (f), 0.8% formaldehyde
reated gradient-purified EIAV (M), EIAV attached to iron oxide beads (F),
IAV attached to iron oxide beads and treated with 0.8% formaldehyde (E),
IAV attached to iron oxide beads sonicated (), the supernatant of EIAV
ttached to iron oxide beads sonicated (L), or BSA attached to iron oxide
eads (*). Virus production at the various times postaddition in the super-
atant of the incubated cells was measured in a micro-reverse transcrip-
ase assay as described under Materials and Methods. Data points were
onducted in triplicate. S.D.s for all data were always ,15%. Data pre-
ented were representative of two separate experiments.ere negative for RT activity (Figs. 1A and 1B).
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39EIAV PARTICULATE VACCINEWe next tested the possibility that infectious virions
ight freely dissociate from the particulate antigen prep-
rations. EIAV-beads in PBS were briefly sonicated in an
ltrasound waterbath to dissociate any virions that were
ot covalently associated with the iron oxide particles.
he supernatant of the sonicated particulates was trans-
erred to equine macrophages and equine dermal cells
nd measured for RT activity in the cell culture medium.
ll sonicated particulate preparations added to both cell
ypes were negative for RT activity (Figs. 1A and 1B).
onicated EIAV-beads supernatants were negative for
rotein content as measured in a Lowry-based microtiter
ssay and by Western blot analysis of pelleted superna-
ants (data not shown). Therefore EIAV-beads were de-
ermined to contain covalently bound virions that were
ot infectious.
n vitro cell-mediated immune responses elicited by
mmunization with EIAV-beads
The virus–particulate complex was compared with sol-
ble, infectious, gradient-purified EIAV for its ability on
ddition to equine macrophages to elicit an in vitro sec-
ndary immune response by primed T cells isolated from
IAV-infected ponies. The antigen presenting cell used in
his assay was the macrophage, the predominant in vivo
arget for replication of EIAV (Montelaro et al., 1993).
acrophages have the capacity to process and present
xogenous particulate antigens with MHC class I mole-
ules (Rock, 1996). Autologous macrophages that had
rocessed and presented EIAV antigens after the initia-
ion of a productive infection by infectious gradient-puri-
ied EIAV or after pulsing with EIAV-beads effectively
timulated EIAV-specific oligoclonal T cells to incorpo-
ate [3H]thymidine in a dose-dependent manner (Fig. 2A).
he responding T cells in the cultures induced by the
ddition of gradient-purified EIAV were ;70% CD41, with
ome cells CD81 (10–15%) as determined by indirect
mmune fluorescence (data not shown). In contrast, the
esponding T cell cultures on addition of the particulate
reparation were .65% CD81, with few (,15%) CD41
ells observed (data not shown). Maximum levels of
timulation occurred with the addition of 3–10 mg/ml of
radient-purified EIAV and 3 mg/ml of gradient-purified
IAV coupled to beads. The addition of particulate anti-
ens at .10 mg of antigen/ml elicited toxic effects on the
acrophages due to an overabundance of particles
hagocytosed by the cells, which in turn resulted in a
eduction in the level of the observed lymphoproliferation
Fig. 2A). Autologous macrophages pulsed with BSA con-
ugated to iron oxide particles did not induce any anti-
en-specific response by the T cells (Fig. 2A). Thus EIAV
resented to macrophages in the form of a noninfectious
articulate was processed and presented for recognition
y predominantly virus-specific CD81 T cells.We compared and contrasted the antigen-specific cy-olytic effector functions of the responding T cell popu-
ations isolated from long-term EIAV-infected ponies to
acrophages that had been pulsed with infectious gra-
ient-purified EIAV or EIAV-beads. EIAV infected macro-
hages activated and expanded both CD41 env-specific
nd CD81 gag-, pol-, and env-specific CTL (Fig. 2B). In
ontrast, the macrophages pulsed with EIAV-beads acti-
ated and expanded only CD81 gag- and env-specific
TL (Fig. 2C). The lower level of env-specific CTL com-
ared with the gag-specific CTL and the lack of pol-
pecific CTL in cultures activated and expanded by mac-
ophages pulsed with particulate antigen was consis-
ently observed in all replicate experiments. Thus EIAV-
nfected macrophages and macrophage-pulsed with
IAV-beads activated and expanded responding T cell
opulations that differed in antigen specificity and phe-
otype.
mmunization with an inactivated whole virus
articulate vaccine
To evaluate the in vivo effectiveness of the EIAV-beads
reparation to elicit a cell-mediated immune response,
e initiated a vaccination protocol for which four naive
utbred ponies were inoculated with the EIAV-beads
reparation. Clinical evaluations were performed daily
n all animals. Immunological responses were moni-
ored at predetermined intervals after initiation of the
accine. Both cell-mediated (EIAV-specific lymphoprolif-
rative and CTL responses) and humoral (env-specific
ntibody quantity and quality as measured in neutraliza-
ion, avidity, and conformation analyses) responses were
ollowed.
All animals received 200 mg of EIAV-beads divided
venly on either side of the neck and administered a total
f three times with 3 weeks between each inoculation.
linical observations and temperature profiles were
onitored daily, and platelet counts were monitored
eekly after initiation of the particulate regimen (Fig. 3).
o evidence of a pathogenic EIAV infection in the form of
temperature above 39°C, platelet count below 105,000/
l, or any clinical signs was observed before infectious
irus challenge.
To further detect any productive replication of the EIAV-
eads after the administration of the immunogen, we
onducted two in vitro measurements of viremia: levels
f infectious virus and copies of viral RNA present in
lasma. On the day of virus challenge, no infectious virus
s measured by culturing undiluted plasma onto permis-
ive fetal equine kidney cells or viral RNA as measured
y semiquantitative RT-PCR were detectable in the
lasma of the vaccinated animals (Table 1). These re-
ults, together with clinical observations, confirm the
ack of a productive infection in the animals receiving the
IAV-beads vaccine regimen.Ponies were inoculated with EIAV-beads to elicit an
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40 HAMMOND ET AL.IAV-specific cell-mediated immune response to evalu-
te the role of T cells in the control or prevention of an
IAV infection. Strong lymphoproliferative responses by
oth CD41 and CD81 T cells to autologous macro-
hages infected with EIAV were observed (stimulation
ndices of 15–35) at the day of virus challenge (Fig. 4).
hese results clearly established that the particulate
accine generated a readily detectable cell-mediated
esponse. Qualitative analyses of the cell-mediated re-
ponse by measuring EIAV-specific CTL activity from the
accinated subjects at day of challenge, however, de-
ected statistically significant activity in standard chro-
ium release assays for only one pony in the study, pony
21 (Fig. 5B). The lack of readily detectable CTL activity
bserved in the peripheral blood leukocytes (PBLs) col-
ected from the vaccinates was confirmed by conducting
xperiments in which PBLs were activated and ex-
anded in vitro with one of two methods in parallel:
utologous macrophages infected with EIAV or autolo-
ous pokeweed mitogen (PWM)-stimulated lymphoblasts
nfected with recombinant vaccinia virus vectors carrying
equences encoding EIAV gag, pol, and env. To increase
he potential for lytic activity to be observed, all responding
ffector cell populations were enriched for CD81 T cells by
ndirect panning or positive selection for CD81 T cells.
onetheless, only pony 621 had any detectable cytolytic
ctivity on target cells expressing EIAV antigens (Fig. 5B).
Quantitative and qualitative humoral immune analyses
f the envelope glycoprotein-specific antibody elicited by
he particulate vaccine regimen were analyzed at the day
f challenge (DC) using measurements of serum anti-
ody titer, avidity, conformation, and neutralizing capa-
ilities (Fig. 6). Quantitative analysis of env-specific an-
ibody demonstrated the presence of moderate levels
reciprocal end point titers ;103) of the antibody popu-
ations in all animals tested (Fig. 6A). Although env-
pecific antibody was present in all animals, we were
nable to detect any neutralizing activity to autologous
irus in our standard neutralization assay (Fig. 6B). Avid-
ty index measurements of the envelope-specific anti-
ody were extremely low (,5%) for all animals in this trial
Fig. 6C). Conformational ratio analyses of env antibody
eactivities to native or denatured viral envelope glyco-
roteins demonstrated a predominance (ratios 1.7–3.3) of
sed at various effector-to-target ratios in a standard chromium release
ssay after no treatment (undepleted), after depletion of CD81 cells, or
fter depletion of CD41 cells. After depleting the specific subpopula-
ions, effector cell addition at the various effector-to-target ratios were
ormalized appropriately according to the original CD4/CD8 ratios
easured by flow cytometry in the undepleted effector population.
utologous target cells were generated by infection with recombinant
accinia virus vectors carrying sequences encoding EIAV gag (f), pol
), env (E), or b-galactasidase (starbursts). Data presented is repre-
entative of 2 separate experiments. SEM for all data points wasFIG. 2. In vitro secondary cell-mediated immune responses medi-
ted by EIAV covalently coupled to iron oxide beads. (A) Nonadherent
BLs isolated from long-term EIAV infected ponies were mixed with
utologous macrophages infected with varying amounts of gradient-
urified EIAV (f), pulsed with varying amounts of EIAV attached to iron
xide beads (E), or pulsed with varying amounts of BSA attached to
ron oxide beads (starbursts). Proliferation was measured by [3H]thy-
idine incorporation 5 days postaddition and was presented in the
orm of an SI that represented [3H]thymidine incorporation of antigen-
timulated cultures divided by [3H]thymidine incorporation of unstimu-
ated cultures. Mean incorporation of [3H]thymidine of replicate un-
timulated lymphocyte cultures were always ,400 cpm. All experi-
ents were conducted in quadruplicate. The graph shown was a
epresentative of three experiments. The SI S.E.M. for each data point
as always ,10%, as calculated under Materials and Methods. (B and
) PBLs isolated from long-term infected ponies were activated and
xpanded in vitro with autologous macrophages infected with 10 mg/ml
radient-purified EIAV (B) or pulsed with 3 mg/ml gradient-purified EIAVlways ,3%.
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41EIAV PARTICULATE VACCINEntibody specificity for conformation-dependent epitopes
ver linear epitopes (Fig. 6D). Taken together, the quan-
itative and qualitative measurements of the humoral
mmune response induced by the EIAV-beads suggested
relatively immature antibody response as described for
he lentivirus model systems of EIAV (Hammond et al.,
997)and SIV (Cole et al., 1997).
irus challenge of vaccinated ponies
Nonvaccinated ponies experimentally infected with
FIG. 3. Clinical profiles of ponies inoculated with EIAV-beads before
hallenge with infectious EIAV. Four outbred ponies (579, 621, 645, and
49) were inoculated intradermally with 200 mg of EIAV attached to iron
xide particulates at the indicated time points (arrows) before chal-
enge with infectious EIAV. Rectal temperatures in degree centigrade
ere plotted using the primary y-axis (solid line). Platelet counts per
icroliter of whole blood were represented on the graphs using the
econdary y-axis (F). Arrows indicate the days on which the ponies
ere inoculated with immunogen.IAVPV progressed to clinical EIA in ;16–19 days (Figs. aE and 7F; Table 1). Concurrent with the initial EIA-
elated fever was a rapid decline in the quantity of plate-
ets circulating in the blood. In some cases of EIAV
nfection, ponies recrudesce with more severe clinical
anifestations of high fever (.39°C) and extremely low
lood platelet counts of ,105,000/ml of blood (Fig. 7F).
uantities of viral RNA in excess of 106 copies/ml of
lasma were measured in as little as 14 days postinfec-
ion from most nonvaccinated ponies experimentally in-
ected with EIAV (Table 1). Thus in animals with a naive
mmune system to EIAV, this strain of EIAV induces an
cute syndrome characterized by a disseminate disease
hat rapidly overcomes the host’s immune defenses dur-
ng the initial stage of infection.
In contrast to naive animals, ponies vaccinated with
he EIAV-beads preparation demonstrated, in general, a
elay in disease progression and a lower virus burden
Figs. 7A–7D, Table 1). All vaccinated animals were chal-
enged with 300 equid infectious doses of EIAVPV 3
eeks after the final immunization. Interestingly, one
nimal, pony 579, did not show any clinical signs of
isease during the 65 days of observations in the form of
febrile episode or a drop in platelet counts below
05,000/ml after challenge with infectious EIAV (Fig. 7A).
f the three remaining animals, two ponies, 621 and 649,
ad a delay in the progression to disease (44 and 58
ays after virus challenge) compared with nonvaccinated
nd experimentally infected ponies (16–21 days after
irus challenge). The single remaining pony, 645, pro-
ressed to disease at the same rate as naive animals
xperimentally challenged with infectious virus.
The initial day postchallenge at which infectious virus
ould be detected in vitro was delayed in the vaccinates
Table 1), from 8–13 days after virus challenge in nonvac-
inates and 14 to .22 days after virus challenge in
accinates. Comparing and contrasting the viral RNA
evels using semiquantitative RT-PCR of the three immu-
ized ponies that had a delay in disease (579, 621, and
49) to the nonimmunized ponies at 21 days after virus
hallenge resulted in, on average, 1000-fold less viral
NA in the vaccinates than the control animals (Table 1).
tatistical analysis comparing the virus RNA levels at
ay 21 postchallenge in animals receiving the particulate
accine with a panel of nonvaccinated animals (Table 1)
sing a nonparametric, two-tailed Mann-Whitney test re-
ulted in a value of P , 0.01. This result emphasized the
ositive effects of the particulate vaccine by providing a
tatistically significant correlation between the reduction
n virus burden to the observed delay in disease progres-
ion for the group of animals in the vaccine study.
namnestic responses to virus challenge in
mmunized ponies
Anamnestic cellular and humoral immune responses
fter virus challenge were measured in animals receiv-
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42 HAMMOND ET AL.ng the particulate vaccine compared with nonvaccinated
nimals. EIAV-specific CTL were not readily observed on
he day of virus challenge in three of four animals immu-
ized with the particulate vaccine regimen (Fig. 5B). In
ontrast, env- and/or gag-specific CTL was readily de-
ected in two of four vaccinated animals (621 and 649) 9
eeks after virus challenge (Fig. 5C). Moreover, statisti-
ally significant but very low levels of CTL were observed
n the other two vaccinated ponies in the study (Fig. 5C).
he levels of CTL activity observed in the vaccinates
ere consistent with the transient levels of EIAV-specific
TL activity (0–40% specific lysis) measured within the
irst 9 weeks after virus challenge in nonvaccinated po-
ies receiving the same amount of infectious virus (Ham-
ond et al., 1997).
Interestingly, the anamnestic humoral immune re-
ponses differed markedly from the cell-mediated im-
une responses in the vaccinates in that EIAV-specific
ntibody both quantitatively and qualitatively equaled or
urpassed the measured levels in nonvaccinated virus
nfected ponies. The env-specific antibody levels in the
accinates increased rapidly in the 3 weeks after intro-
uction of infectious virus (Fig. 6A). By 6 weeks after
irus challenge, quantitative levels of env-specific anti-
ody reached a maximum in a similar manner as non-
accinated animals. Although the vaccinated ponies
ere primed with antigen before virus challenge, the
T
Kinetics of Virus Replication in Vaccinate
Pony no.
Plasma viremia level
on day of challenge
Viral RNA leve
Day of challenge 7 days
579 Neg.e ,102f 3 3 10
621 Neg. ,102 ,10
645 Neg. ,102 6 3 10
649 Neg. ,102 1 3 10
Control poniesi
6 N/Aj N/A ,10
49 N/A N/A ,10
98 N/A N/A 2 3 10
561 N/A N/A ,10
562 N/A N/A ,10
564 N/A N/A ,10
567 N/A N/A ,10
a Viral RNA molecules per milliliter were calculated by semiquantita
b Days postinoculation.
c Plasma collected this day post virus inoculation resulted in a pos
ultures.
d The first day post virus challenge during which a rectal temperatu
e Plasma collected on the day of challenge resulted in no measurea
f The lower limit of the assay was determined to be 102 molecules p
g This pony did not have a temperature above 39°C during the stud
h No samples were tested after 22 days post virus inoculation.
i Ponies listed were nonvaccinated and challenged with EIAVPV (Ham
j Does not apply (N/A).ABLE 1
d and Control Ponies Challenged with EIAVPV
ls (molecules/ml)a
Day postchallenge
of initial viremiac
Day postchallenge
of initial EIA feverdp.i.b 14 days p.i. 21 days p.i.
2 8 3 102 5 3 103 16 N/Ag
2 8 3 102 1 3 103 .22h 44
2 1 3 104 1 3 105 14 18
2 5 3 102 1 3 103 15 58
2 2 3 103 2 3 107 13 19
2 4 3 103 5 3 105 11 18
5 1 3 108 1 3 107 8 21
2 2 3 106 2 3 106 11 16
2 2 3 106 3 3 105 11 17
2 8 3 105 2 3 106 12 18
2 2 3 106 1 3 106 11 18
tive RT-PCR.
itive RT measurement when incubated undiluted on fetal equine kidney cell
re above 39°C was measured.
ble RT activity when incubated undiluted on fetal equine kidney cell cultures.
er ml.
y.
mond et al., 1997; Raabe et al., 1998).riming with EIAV-beads did not induce quantitatively a uFIG. 4. In vitro lymphoproliferative responses of PBLs isolated from
IAV-bead vaccinated ponies to EIAV-infected autologous macro-
hages. PBMC samples collected longitudinally from the four vacci-
ated outbred ponies (579, 621, 645, and 649) were analyzed for lym-
hoproliferative responses to autologous macrophages infected with
IAVPV, as described under Materials and Methods. The lymphoprolif-
rative reactivities were presented in the form of an SI representing
3H]thymidine incorporation of antigen-stimulated cultures divided by
3H]thymidine incorporation of unstimulated cultures. Mean incorpora-
ion of [3H]thymidine of replicate unstimulated lymphocyte cultures
ere always ,400 cpm. All experiments were conducted in quadru-
licate. The y-axis error bars represent the SI S.E.M. as calculated
nder Materials and Methods.
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43EIAV PARTICULATE VACCINEore rapid env-specific humoral immune response to
nfectious EIAV than nonvaccinates. Similar temporal an-
mnestic responses in vaccinates and nonvaccinates
FIG. 5. CTL activity present in ponies before vaccination, at the day o
nfected ponies before administration of the vaccine (A), on the day of
xpanded in vitro in parallel with one of two methods: autologous ma
nfected with three separate recombinant vaccinia virus vectors carryin
sed at an effector-to-target ratio of 30:1 in a standard chromium releas
arget cells were generated by infection with recombinant vaccinia viru
second from the left), env (third from the left), or pol (right bars). NK c
hromium release assays (data not shown). Data presented are repre
lways ,3%.ere observed when measuring the stability of the anti- een–antibody complexes in an avidity ELISA (Fig. 6C). In
ontrast to the lack of differences between the vacci-
ates and nonvaccinates in the quantitative amounts of
hallenge, and at 9 weeks postchallenge. PBLs isolated from long-term
hallenge (B), or 9 weeks after virus challenge (C) were activated and
ges infected with EIAV or autologous PWM-stimulated lymphoblasts
ences encoding EIAV gag, pol, and env. The responding cultures were
y after depletion of CD41 cells to enrich for CD81 T cells. Autologous
rs carrying sequences encoding b-galactasidase (left bars), EIAV gag
activity was not observed on using nonautologous target cells in the
ve of three separate experiments. The S.E.M. for all data points wasf virus c
virus c
cropha
g sequ
e assa
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44 HAMMOND ET AL.ifferences were observed qualitatively (neutralization
ctivity and conformational epitope dependence), with
he env-specific antibody in the ponies receiving the
IAV-beads vaccine compared with nonvaccinates. Neu-
ralizing antibody activity present in the serum of vacci-
ates rapidly increased to high levels of .1:300 dilution
or a 50% neutralizing antibody titer just 3 weeks after
irus challenge (Fig. 6B). This observation is in sharp
ontrast to the lack of neutralizing antibody (,1:10) even
t 9 weeks postinfection in nonvaccinated animals (Fig.
B). Similarly, the predominance of conformational
pitopes of the env-specific antibody populations in vac-
inated animals present at the day of challenge in-
reased markedly from an average of 2.3 to 3.5 during
he time of observation (Fig. 6D). In contrast, env-specific
ntibody responses in naive ponies were initially di-
ected to linear determinants (at 3 weeks postinfection,
FIG. 6. Quantitative and qualitative measurements of serum antibodie
gG reactivity to EIAV envelope glycoproteins was measured in a conca
eparated into two parts for rapid visual comparison. Sera were collec
eeks after virus challenge (6wk PC), and 9 weeks after virus challeng
nd collected at 3 weeks postinfection (3wk PI), 6 weeks postinfectio
nimals infected with EIAV (right). Results are the averages of at least t
F) were presented on the vaccinated half of each panel. Data from p
nfected with EIAVPV, were presented on the nonvaccinated half of each
gG present in serum collected at various time points from vaccinated
he 50% reciprocal neutralizing antibody titer measured in serum co
hallenged with infectious EIAV. The S.D. was always ,6%. (C) The avid
ime points from vaccinated and nonvaccinated ponies challenged with
gG present in serum collected at various time points from vaccinated an
alue of .1.0 (dotted line) signifies a predominance of the antibody popu
atio of ,1 signifies a predominance of the antibody population specionformation ratio was 0.7) and became predominantly nonformational (ratio .1) after 6 weeks postinfection
Fig. 6D). Thus the EIAV-beads preparation appeared to
nduce an env-specific antibody population adept at rec-
gnizing and responding more rapidly to conformation-
lly dependent and neutralizing epitopes present on viri-
ns. Taken together, this vaccine regimen, although not
liciting a detectable virus-specific CTL response, in-
uced positive immunological responses that delayed
isease progression, reduced virus burden, and pro-
ided a rapid anamnestic humoral response highlighted
y considerable amounts of virus neutralizing activity.
DISCUSSION
We present here the first study using a particulate
mmunization strategy in a large animal model. Our re-
ults demonstrate that a virus particulate vaccine, while
vaccinated ponies specific for the EIAV envelope glycoprotein. Serum
A ELISA as described under Materials and Methods. Each panel was
the day of challenge (DC), 3 weeks after virus challenge (3wk PC), 6
PC) from outbred ponies vaccinated with the EIAV-beads vaccine (left)
PI), and 9 weeks postinfection (9wk PI) from nonvaccinated control
ependent assays. Data from ponies 579 (L), 621 (f), 645 (), and 649
61(L), 562 (f), 564 (), and 567 (F), which had been experimentally
. (A) Reciprocal end point titer quantification of EIAV envelope-specific
nvaccinated ponies that had been challenged with infectious EIAV. (B)
at various time points from vaccinated and nonvaccinated ponies
ex of EIAV envelope-specific IgG present in serum collected at various
ous EIAV. (D) The conformation dependence of EIAV envelope-specific
accinated ponies challenged with infectious EIAV. A conformation ratio
specific for conformation dependent epitopes, whereas a conformation
inear epitopes.s from
navalin
ted at
e (9wk
n (6wk
wo ind
onies 5
panel
and no
llected
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45EIAV PARTICULATE VACCINEation and delayed the development of disease in three
f four immunized ponies challenged with homologous
irus. Indeed, we established a statistically significant
orrelation between levels of virus replication and delay
f disease progression in the vaccinated ponies com-
ared with nonvaccinated ponies. In general, the vacci-
FIG. 7. Clinical profiles of vaccinated ponies after challenge with hom
latelet counts per microliter of whole blood (F, secondary y-axis) of fou
ntradermally with a total of 600 mg of EIAV attached to iron oxide bea
ontrol ponies (E and F; ponies 562 and 564) that had not been immu
xcess of 39°C were considered specific EIA-related episodes.ated ponies with a delay in disease progression had on lverage up to 1000-fold lower viral RNA levels in the
lasma at days 14 and 21 after virus challenge than the
ontrol ponies. Taken together, our findings indicate that
he particulate vaccine regimen elicited immune re-
ponses providing partial protection for ponies on chal-
enge with infectious virus. Although we demonstrated a
us infectious EIAV. Rectal temperatures (solid line, primary y-axis) and
d ponies (A–D; ponies 579, 621, 645, and 649) that had been inoculated
re challenge on day 0 with infectious EIAVPV and two representative
but were experimentally infected with EIAVPV. Rectal temperatures inologo
r outbre
ds befo
nizedevel of protection induced by the vaccine regimen, these
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46 HAMMOND ET AL.tudies do not identify any obvious immune correlates of
rotection at the day of challenge. However, within 3
eeks after virus challenge, anamnestic humoral re-
ponses characterized by a rapid emergence of neutral-
zing activity in the serum and a predominance of anti-
odies to conformationally dependent epitopes were ob-
erved in the vaccinates, indicating a beneficial priming
ffect elicited by the particulate vaccine that could be
easured in vitro.
Previous evaluations of candidate EIAV vaccines to
licit protective immune responses against challenge
ith pony virulent virus reveal a broad spectrum of
accine efficacy in preventing EIAV infection and the
evelopment of disease (Montelaro et al., 1996). Ponies
mmunized with a baculovirus-expressed recombinant
nvelope glycoprotein subunit (rgp90) vaccine and sub-
equently challenged with pony virulent virus produced a
ange of vaccine efficacies ranging from lack of clinical
isease to severe enhancement (Raabe et al., 1998). The
gp90 trial was similar to this study because all ponies in
oth trials had measurable viral RNA levels in their
lasma. However, the rgp90 immunogen elicited severe
nhancement of infection in some vaccinated ponies that
as not observed in our particulate vaccine study. Po-
ies vaccinated with an inactivated whole virus or a
ectin affinity-purified viral envelope glycoprotein were
terilely protected against homologous avirulent chal-
enge (Issel et al., 1992). However, only the whole virus
accine, and not the glycoprotein vaccine, was able to
rotect ponies against infection on challenge with het-
rologous pony virulent virus. At the day of challenge,
oth the whole virus and glycoprotein vaccinates, as well
s the particulate vaccinates in this study, had no de-
ectable neutralizing antibody. Interestingly, anamnestic
eutralizing antibody responses to the challenge virus
train were observed in animals that received the par-
iculate vaccine but not the inactivated whole virus vac-
ine. Therefore, detectable anamnestic virus neutralizing
ntibody may not be a necessary component of a pro-
ective immune response to prevent establishment of
nfection on challenge by exogenous virus.
Particulate vaccines are noted for their ability to prime
vigorous antigen-specific CTL response in vivo (Falo et
l., 1995). Nevertheless, by day of challenge our partic-
late vaccine induced a vigorous virus-specific lympho-
roliferative response with little measurable CTL activity.
ur initial in vitro studies using EIAV covalently associ-
ted with iron oxide beads to prime antigen presenting
ells demonstrated a potent virus-specific lymphoprolif-
rative activity. Moreover, use of autologous macro-
hages primed with virus-coupled particulates to acti-
ate and expand virus-specific CTL in vitro led our group
o believe that this priming mechanism would be very
fficacious in vivo. We have considered several param-
ters that may have contributed to the absence of virus-
pecific CTL activity in animals receiving the EIAV-beads smmunogen. First, this was the first study to analyze in a
arge animal model system the effectiveness of a partic-
late preparation to prime for viral immunity. Therefore it
s conceivable that we did not immunize the animals with
ufficient antigen preparation to effectively replicate the
nduction of immunity as in the murine model system.
econd, the multicomponent nature of the immunogen
ould have diluted the levels of antigen below a thresh-
ld necessary to effectively prime antigen-specific CTL
n sufficient quantities for measurement from peripheral
lood mononuclear cells (PBMCs) in our in vitro assay.
hird, our detection methods may not have been sensi-
ive enough to accurately detect the virus-specific CTL
nduced by the particulate vaccine even though sufficient
ntigen was provided during the immunizations for an
ffective virus-specific CTL response to be generated
ystemically. Activating and expanding CTL in in vitro
ulture for 7 days is much less accurate in measuring
ntigen-specific CTL than direct measurements of cyto-
ine production at the single cell level using flow cytom-
try or ELISPOT methods (Murali-Krishna et al., 1998).
nfortunately, the reagents to directly measure inter-
eron-g or interleukin-4 production at the single cell level
sing cytokine-specific monoclonal antibodies in ELIS-
OT and/or flow cytometric analyses or MHC tetramer
echnology for direct quantification of antigen-specific T
ells is not yet available in the equine system.
At the day of challenge, the EIAV-beads regimen in-
uced an “immature” humoral immune response of mod-
rate titer, low avidity, and non-neutralizing activity, sub-
tantiating our previous studies suggesting that a mature
mmune response will be required for protective immu-
ity (Cole et al., 1997; Hammond et al., 1997). Interest-
ngly, anamnestic humoral immune responses after virus
hallenge were associated with an increase in antibody
iter, the rapid emergence of strong neutralizing antibody
ctivity, and the maintenance of the predominance of
onformationally dependent env-specific epitopes.
trong anemnestic neutralizing antibody responses to
IV infection were similarly observed in macaques ini-
ially receiving cell-free replication-incompetent SIV in-
ravenously or SIV in adjuvants intramuscularly and
oosted subcutaneously with particulate SIV (Kraisel-
urd et al., 1997). These observations suggest the po-
ential effectiveness of a particulate vaccination regimen
o induce antibody responses specific for proteins in a
ore native form, whereas adjuvanted antigens may
resent epitopes in a more denatured or masked format.
ur observations indicate that the effective production of
eutralizing antibodies to lentiviral envelope glycopro-
eins may depend on the qualitative means by which the
ntigen is presented to the humoral arm of the immune
ystem.
In this initial study, EIAV-beads vaccine regimen did
ot induce protective or sterile immunity to virus expo-
ure. Several parameters could be evaluated more thor-
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47EIAV PARTICULATE VACCINEughly to provide a more effective vaccine regimen in
his large animal model. These parameters include the
mount of viral protein at each inoculation, the number of
mmunizations, and the period of immunization before
irus challenge. Moreover, further studies using selected
IAV subunit antigens coupled to particulate beads in-
tead of a multicomponent virus particle may prove to be
more effective approach. Clearly, more studies using
articulate antigens should be conducted in various
arge animal model systems to properly develop and use
his vaccination strategy as a means to induce protective
mmunity.
MATERIALS AND METHODS
IAV strains
Three reference strains of EIAV were used in this
tudy. EIAVPr is the prototype, nonpathogenic, cell cul-
ure-adapted strain of EIAV initially derived by cell adap-
ation of the Wyoming strain of EIAV (Malmquist et al.,
973). EIAVPV is a pathogenic and antigenic variant de-
ived from EIAVPr (Rwambo et al., 1990). EIAVWSU5 is a
irulent strain of EIAV generated using procedures de-
cribed to produce EIAVPV (McGuire et al., 1994). These
hree strains of EIAV are very closely related, having ,1%
ivergence at the amino acid level.
xperimental subjects, clinical evaluation, and sample
ollection
Four outbred ponies were selected for this study. All
onies were clinically monitored daily and maintained as
escribed previously (Issel et al., 1992). Rectal tempera-
ures and clinical status were recorded daily. Samples of
erum, plasma, and whole blood were collected from
ach pony at predetermined intervals. Plasma samples
ere collected at predetermined specified intervals and
uring each febrile episode (.39°C). Plasma samples
ere stored at 280°C until used to determine the quan-
ity of circulating infectious EIAV and of plasma RNA
evels. Serum samples were stored at 220°C until tested
or antibody reactivity in an ELISA, Western blot analysis,
r a neutralization test. Whole blood samples were ap-
ropriately fractionated for enumeration of platelets
Unopette microcollection system; Becton-Dickinson,
utherford, NJ) or experimentation with PBMCs. PBMCs
ere either used the same day for the evaluation of
IAV-specific proliferative responses and EIAV-specific
ytolytic activity or stored in liquid nitrogen for reevalu-
tion.
ntigen preparation and vaccination procedure
Gradient-purified EIAVPV was produced as described
reviously (Montelaro et al., 1982). A particulate form of
radient-purified EIAVPV was constructed by covalently
oupling virus to glutaraldehyde-activated 0.5- to 1.5-mm cron oxide beads (Advanced Magnetics, Cambridge, MA)
s described previously (Falo et al., 1995). The quantity of
irus bound to the particulates was indirectly inferred by
subtractive measurement of the amount of virus origi-
ally in the preparation from the amount of virus remain-
ng after covalent conjugation to the beads as deter-
ined with a Lowry-based assay (BioRad). Where indi-
ated, gradient-purified EIAV was formaldehyde
nactivated as described previously (Issel et al., 1992),
nd gradient-purified EIAV bound to iron oxide particu-
ates was subjected to 0.8% formaldehyde in 13 PBS for
8 h at 4°C, neutralized with 2% sodium bisulfite in 13
BS, and extensively washed with 1X PBS before use in
n vitro or in vivo experiments. Animals were inoculated
n each side of the neck intradermally with a total of 200
g of EIAVPV covalently coupled to iron oxide beads in
aline. Each pony received a total of three inoculations at
ntervals of 3 weeks. All animals were challenged with
00 equid infectious doses of EIAVPV 9 weeks after re-
eiving the initial injection of vaccine.
icro-reverse transcriptase assay
The measurement of reverse transcriptase activity in
he cell supernatants was conducted using a micro-
everse transcriptase assay for EIAV developed in this
aboratory (Lichtenstein et al., 1995) and described else-
here (Raabe et al., 1998). Macrophage and equine
ermal cells used to culture virus were isolated and
aintained as described previously (Raabe et al., 1998).
emiquantitative RT-PCR measurement of plasma
irus levels
Plasma samples from all ponies were analyzed for the
resence of viral RNA using a semiquantitative RT-PCR
ssay that used gag-specific amplification primers (Lich-
enstein et al., 1995). All samples were conducted in a
inimum of two independent experiments.
uantitative and qualitative serological assays
Serum IgG antibody reactivities to EIAV envelope gly-
oprotein were quantitatively (end point titer) and quali-
atively (avidity index, conformation ratio) measured us-
ng a concanavalin A-based ELISA method as described
Hammond et al., 1997). Virus neutralizing activity medi-
ted by immune sera was assessed in an indirect cell
LISA-based, infectious center assay using a constant
mount of infectious EIAVPV and sequential 2-fold dilu-
ions of serum (Hammond et al., 1997).
ymphocyte proliferation assays
EIAV-specific proliferative responses were measured
y using autologous EIAVPV-infected monocytes as anti-
en presenting cells (Hammond et al., 1997). EIAV-spe-
ific lymphocyte proliferative responses were reported in
t
a
i
d
r
E
u
c
v
R
h
1
f
a
r
l
r
M
v
1
i
a
(
C
r
(
p
v
t
i
a
e
i
v
e
c
n
o
c
w
l
w
c
f
n
c
l
b
S
a
5
D
K
t
l
S
p
v
h
M
o
R
t
C
R
v
o
C
C
F
H
H
I
I
K
K
L
48 HAMMOND ET AL.he form of a stimulation index (SI) representing the
verage [3H]thymidine incorporation of replicate EIAV-
nfected monocyte stimulated lymphocyte cultures (E)
ivided by the average [3H]thymidine incorporation of
eplicate unstimulated lymphocyte cultures (M), or SI 5
/M. Median incorporation of [3H]thymidine of replicate
nstimulated lymphocyte cultures were always ,400
pm. The SI ratio S.E.M. was calculated as defined pre-
iously (Hammond et al., 1997).
ecombinant vaccinia virus vectors
The control recombinant vaccinia virus vector (vac)
as been described in detail (vSC8; Chakrabarti et al.,
985). The recombinant vaccinia virus vector carrying the
ull-length EIAVWSU5 env gene (vac-env) has been char-
cterized previously (vENV2; McGuire et al., 1994). The
ecombinant vaccinia virus vectors carrying the full-
ength EIAVPr gag (vac-gag) and pol (vac-pol) were de-
ived from the EIAVPr proviral clone (accession no.
16575). Target cells were infected with recombinant
accinia viruses at a multiplicity of infection of 10 for
2–18 h at 37°C. More than 99% of the equine target cells
nfected with recombinant vaccinia viruses expressed
ntigen as determined by indirect immunofluorescence
data not shown).
TL assay
Cytolytic activity was measured in a standard 51Cr-
elease assay developed for the equine model system
Hammond et al., 1997, 1998). PBMCs were isolated from
onies at designated intervals postvaccination or after
irus challenge by discontinuous density gradient cen-
rifugation. PBMCs were activated and expanded in vitro
n parallel with one of two types of stimulator cells:
utologous macrophages infected with EIAV (Hammond
t al., 1997)or autologous PWM-stimulated lymphoblasts
nfected with three individual recombinant vaccinia virus
ectors carrying sequences encoding EIAV gag, pol, and
nv (Hammond et al., 1998). In vitro depletion of CD41 T
ells was conducted using the method of indirect pan-
ing (McGuire et al., 1994). Generally, .95% of the CD41
r CD81 T cells were depleted as determined by flow
ytometry analysis (data not shown). All experiments
ere performed in quadruplicate. The percent specific
ysis was calculated as follows:
% Specific lysis 5
(E 2 C)
(N 2 C)
3 100
here E is the average cpm from experimental wells
ontaining T cells and target cells, C is the average cpm
rom control wells containing target cells only (sponta-
eous lysis), and N is the average cpm from control wells
ontaining target cells in 0.5% Nonidet P-40 (maximal
ysis). Spontaneous lysis of the target cells was always
elow 30% of maximal lysis. The percent specific lysis.E.M., determined as described previously (Siliciano et
l., 1985), was always ,3%.
ACKNOWLEDGMENTS
This work was supported by National Institutes of Health Grant
RO1-AI25850 from the National Institutes of Allergy and Infectious
isease, by funds from the Lucille Markey Charitable Trust, and by the
entucky Agricultural station. S.A.H. was supported by National Insti-
utes of Health AIDS Training Grant 5T32-AI07487. We thank Ms. Kath-
een Thompson (Department of Dermatology, University of Pittsburgh
chool of Medicine) for technical assistance in the preparation of the
articulate antigens, Dr. Walter Storkus (Department of Medicine, Uni-
ersity of Pittsburgh School of Medicine) for providing the recombinant
uman interleukin-2, Dr. Travis McGuire (Department of Veterinary
icrobiology and Pathology, Washington State University) for gener-
usly providing the vENV2 construct, Dr. Joseph Ahearn (Department of
heumatology, School of Medicine, University of Pittsburgh) for use of
he Beckton Dickenson FACSCalibur flow cytometer, Drs. Sekhar
hakrabarti and Bernard Moss (NIAID and the NIH AIDS Research and
eference Reagent Program) for the recombinant vaccinia virus vector
SC8, and Mr. Gary Thomas and Mr. Brian Meade for their maintenance
f the animal facility and care of the animals.
REFERENCES
hakrabarti, S., Brechling, K. B., and Moss, B. (1985). Vaccinia virus
expression vector: Coexpression of beta-galactosidase provides vi-
sual screening of recombinant virus plaques. Mol. Cell. Biol. 5,
3403–3409.
ole, K. S., Rowles, J. L., Murphey-Corb, M., Clements, J. E., Unangst, T.,
Robinson, J., Desrosiers, R. C., Wyand, M. S., and Montelaro, R. C.
(1997). Evolution of envelope-specific antibody responses in mon-
keys experimentally infected or immunized with SIV and its associ-
ation with the development of protective immunity. J. Virol. 71, 5069–
5079.
alo, L. D., Jr., Kovacsovics-Bankowski, M., Thompson, K., and Rock,
K. L. (1995). Targeting antigen into the phagocytic pathway in vivo
induces protective tumour immunity. Nat. Med. 1, 649–653.
ammond, S. A., Cook, S. J., Lichtenstein, D. L., Issel, C. J., and
Montelaro, R. C. (1997). Maturation of the cellular and humoral
immune responses to persistent infection in horses by equine infec-
tious anemia virus is a complex and lengthy process. J. Virol. 71,
3840–3852.
ammond, S. A., Issel, C. J., and Montelaro, R. C. (1998). General
method for the detection and in vitro expansion of equine cytolytic T
lymphocytes. J. Immunol. Methods 213, 73–85.
ssel, C. J., and Foil, L. D. (1984). Studies on equine infectious anemia
virus transmission by insects. J. Am. Vet. Med. Assoc. 184, 293–297.
ssel, C. J., Horohov, D. W., Lea, D. F., Adams, W. V., Jr., Hagius, S. D.,
McManus, J. M., Allison, A. C., and Montelaro, R. C. (1992). Efficacy
of inactivated whole-virus and subunit vaccines in preventing infec-
tion and disease caused by equine infectious anemia virus. J. Virol.
66, 3398–3408.
ovacsovics-Bankowski, M., and Rock, K. L. (1994). Presentation of
exogenous antigens by macrophages: analysis of major histocom-
patibility complex class I and class II presentation and regulation by
cytokines. Eur. J. Immunol. 24, 2421–2428.
raiselburd, E., Salaman, A., Beltra´n, M., Rivera, M., Oliver, J., Kessler,
M., Knezevich, M., Rodriguez, A., Bilska, M., Montefiori, D., Torres-
Bauza, L., and Martinez, I. (1997). Vaccine evaluation studies of
replication-defective SIVsmB7. Cell. Mol. Biol. 43, 915–924.
ichtenstein, D. L., Rushlow, K. E., Cook, R. F., Raabe, M. L., Swardson,
C. J., Kociba, G. J., Issel, C. J., and Montelaro, R. C. (1995). Replication
in vitro and in vivo of an equine infectious anemia virus mutant
deficient in dUTPase activity. J. Virol. 69, 2881–2888.
MM
M
M
M
M
R
R
R
R
S
S
S
49EIAV PARTICULATE VACCINEalmquist, W. A., Barnett, D., and Becvar, C. S. (1973). Production of
equine infectious anemia antigen in a persistently infected cell line.
Arch. Virol. 42, 361–370.
cGuire, T. C., Tumas, D. B., Byrne, K. M., Hines, M. T., Leib, S. R.,
Brassfield, A. L., O’Rourke, K. I., and Perryman, L. E. (1994). Major
histocompatibility complex-restricted CD81 cytotoxic T lymphocytes
from horses with equine infectious anemia virus recognize env and
gag/pr proteins. J. Virol. 68, 1459–1467.
ontelaro, R. C., Ball, J. M., and Rushlow, K. E. (1993). Equine retrovi-
ruses. In “The Retroviridae” (J. Levy, Ed.), Vol. 2, pp. 257–360. Plenum
Press, New York.
ontelaro, R. C., Grund, C., Raabe, M., Woodson, B., Cook, R. F., Cook,
S., and Issel, C. J. (1996). Characterization of protective and enhanc-
ing immune responses to equine infectious anemia virus resulting
from experimental vaccines. AIDS Res. Human Retroviruses 12, 413–
415.
ontelaro, R. C., Lohrey, N., Parekh, B., Blakeney, E. W., and Issel, C. J.
(1982). Isolation and comparative biochemical properties of the ma-
jor internal polypeptides of equine infectious anemia virus. J. Virol.
42, 1029–1038.
urali-Krishna, K., Altman, J. D., Suresh, M., Sourdive, D. J. D., Zajac,
A. J., Miller, J. D., Slansky, J., and Ahmed, R. (1998). Counting antigen-
specific CD8 T cells: A reevaluation of bystander activation during
viral infection. Immunity 8, 177–187.aabe, M., Issel, C., Cook, S., Cook, R., Woodson, B., and Montelaro, R.
(1998). Immunization with a recombinant envelope protein (rgp90) of
EIAV produces a spectrum of vaccine efficacy ranging from lack of
clinical disease to severe enhancement. Virology 245, 151–162.
aabe, M. R., Issel, C. J., and Montelaro, R. C. (1998). Equine monocyte-
derived macrophage cultures and their applications for infectivity
and neutralization studies of equine infectious anemia virus. J. Virol.
Methods 71, 87–104.
ock, K. L. (1996). A new foreign policy: MHC class I molecules monitor
the outside world. Immunol. Today 17, 131–137.
wambo, P. M., Issel, C. J., Hussain, K. A., and Montelaro, R. C. (1990).
In vitro isolation of a neutralization escape mutant of equine infec-
tious anemia virus (EIAV). Arch. Virol. 111, 275–280.
ellon, D. C., Fuller, F. J., and McGuire, T. C. (1994). The immunopatho-
genesis of equine infectious anemia virus. Virus Res. 32, 111–138.
iliciano, R. F., Keegan, A. D., Dintzis, R. Z., Dintzis, H. M., and Shin, H. S.
(1985). The interaction of nominal antigen with T cell antigen recep-
tors. I. Specific binding of multivalent nominal antigen to cytolytic T
cell clones. J. Immunol. 135, 906–914.
tein, C. D., Lotze, J. C., and Mott, L. O. (1942). Transmission of equine
infectious anemia by the stablefly, Stomoxys calcitrans, the horsefly,
Tabanus sulcifrons (Macquart), and by injection of minute amounts of
virus. Am. J. Vet. Res. 3, 183–193.
